KRAS and colorectal carcinoma: The conservation in CAF gene expression between KRAS- or BRAF-driven tumors indicates that any therapeutic targeting of CAF moieties may be efficacious for multiple types of CRC independent of the molecular driver, an important consideration when stratifying clinical patient populations.